TAK Currently At Short EntryTAK showing large wick rejection on weekly. Reward/risk here is 3.0 with trade as pictured and entries scattered across the red zone.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
4.60 MXN
14.50 B MXN
615.70 B MXN
3.15 B
About TAKEDA PHARMACEUTICAL CO LTD
Sector
Industry
CEO
Christophe Weber
Website
Headquarters
Osaka
Founded
1781
FIGI
BBG00N0NV1J1
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Related stocks
TAK : SQUARE ROOT / POSITION TRADEThe Square Root set-up appears in large cap stocks that underwent capitulation. Because large caps are heavily traded, the high liquidity reduces sharp movements. This set-up is best for position trading and usually is a sweet spot for establishing a core position on a stock that potentially has lo
Big Bull Run, 30+ short term, 50+ long term
30 within month
50+ within year
Takeda has made significant moves in the development of it's global pipeline. From the MASSIVE moves with various COVID vaccine manufacturers, to acquiring smaller Immunology biotech startups, and increase in Boston research sphere. I am the most bullish on Takeda
4502 (TSE) - Be CarefullGreetings
Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, do not be hesitant to send us message (inbox). Our Service : Signal recomendation, Trading Course, P
consolidation faze before the breakout ? yeshas potential if 21 can break, can possibly enter here but at the risk of waiting a few months to a year for this trend channel to break to the upside, i prefer waiting for confirmation first! but we all have our own style. goodluck :)
TAK: ReversalIdea,
Inverse cup and handle.
Inverse head and shoulders
RSI divergence double bottom upward trend
top 18...
can it break ATH?
TAK - Takeda Pharma - TO THE MOON? - Major Covid 19 Discovery Researchers tout 'major scientifc discovery' in $14M study for COVID-19 treatment
www.cbc.ca
Close to 4,500 people participated in the study, lead researcher calls findings 'substantial' and 'robust'
CBC News · Posted: Jan 23, 2021 4:07 PM ET | Last Updated: January 23
The $14-million study was fu
TAK LongPossible inverse head and shoulders formation. ARK invest has been loading up shares. looking into June contracts or leaps.
TAKTAK is accumulating and it formed Inverse head and shoulders as well.
Also ARK is loading them in huge ... Get in the boat.
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
TKPH5010047
Takeda Pharmaceutical Company Limited 3.175% 09-JUL-2050Yield to maturity
7.22%
Maturity date
Jul 9, 2050
TKPH5010048
Takeda Pharmaceutical Company Limited 3.375% 09-JUL-2060Yield to maturity
7.11%
Maturity date
Jul 9, 2060
TKPH5010046
Takeda Pharmaceutical Company Limited 3.025% 09-JUL-2040Yield to maturity
6.56%
Maturity date
Jul 9, 2040
TKPH5841810
Takeda Pharmaceutical Company Limited 5.8% 05-JUL-2064Yield to maturity
6.23%
Maturity date
Jul 5, 2064
TKPH5841809
Takeda Pharmaceutical Company Limited 5.65% 05-JUL-2054Yield to maturity
6.08%
Maturity date
Jul 5, 2054
TKPH5841808
Takeda Pharmaceutical Company Limited 5.65% 05-JUL-2044Yield to maturity
5.90%
Maturity date
Jul 5, 2044
TKPH5841807
Takeda Pharmaceutical Company Limited 5.3% 05-JUL-2034Yield to maturity
5.21%
Maturity date
Jul 5, 2034
TKPH5010045
Takeda Pharmaceutical Company Limited 2.05% 31-MAR-2030Yield to maturity
4.88%
Maturity date
Mar 31, 2030
See all TAK/N bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange TAKEDA PHARMACEUTICAL COMPANY LIMITED stocks are traded under the ticker TAK/N.
We've gathered analysts' opinions on TAKEDA PHARMACEUTICAL COMPANY LIMITED future price: according to them, TAK/N price has a max estimate of 368.45 MXN and a min estimate of 285.64 MXN. Watch TAK/N chart and read a more detailed TAKEDA PHARMACEUTICAL COMPANY LIMITED stock forecast: see what analysts think of TAKEDA PHARMACEUTICAL COMPANY LIMITED and suggest that you do with its stocks.
TAK/N stock is 2.22% volatile and has beta coefficient of −0.02. Track TAKEDA PHARMACEUTICAL COMPANY LIMITED stock price on the chart and check out the list of the most volatile stocks — is TAKEDA PHARMACEUTICAL COMPANY LIMITED there?
Today TAKEDA PHARMACEUTICAL COMPANY LIMITED has the market capitalization of 853.52 B, it has decreased by −1.89% over the last week.
Yes, you can track TAKEDA PHARMACEUTICAL COMPANY LIMITED financials in yearly and quarterly reports right on TradingView.
TAKEDA PHARMACEUTICAL COMPANY LIMITED is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
TAK/N earnings for the last quarter are −4.66 MXN per share, whereas the estimation was −0.57 MXN resulting in a −717.28% surprise. The estimated earnings for the next quarter are 3.19 MXN per share. See more details about TAKEDA PHARMACEUTICAL COMPANY LIMITED earnings.
TAKEDA PHARMACEUTICAL COMPANY LIMITED revenue for the last quarter amounts to 148.82 B MXN, despite the estimated figure of 150.69 B MXN. In the next quarter, revenue is expected to reach 150.60 B MXN.
TAK/N net income for the last quarter is −13.87 B MXN, while the quarter before that showed 3.25 B MXN of net income which accounts for −526.02% change. Track more TAKEDA PHARMACEUTICAL COMPANY LIMITED financial stats to get the full picture.
Yes, TAK/N dividends are paid semi-annually. The last dividend per share was 5.65 MXN. As of today, Dividend Yield (TTM)% is 3.76%. Tracking TAKEDA PHARMACEUTICAL COMPANY LIMITED dividends might help you take more informed decisions.
TAKEDA PHARMACEUTICAL COMPANY LIMITED dividend yield was 3.65% in 2024, and payout ratio reached 242.25%. The year before the numbers were 3.75% and 163.50% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 20, 2025, the company has 47.45 K employees. See our rating of the largest employees — is TAKEDA PHARMACEUTICAL COMPANY LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TAKEDA PHARMACEUTICAL COMPANY LIMITED EBITDA is 182.53 B MXN, and current EBITDA margin is 30.32%. See more stats in TAKEDA PHARMACEUTICAL COMPANY LIMITED financial statements.
Like other stocks, TAK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TAKEDA PHARMACEUTICAL COMPANY LIMITED stock right from TradingView charts — choose your broker and connect to your account.